Atagabalin

Atagabalin

File:Atagabalin.svg
Clinical data
Other names	PD-0200390; PD-200390; PD0200390; PD200390
Routes of administration	Oral
ATC code	none
Identifiers
IUPAC name [(3S,4S)-1-(aminomethyl)-3,4-dimethylcyclopentyl]acetic acid
CAS Number	223445-75-8 ☒N
PubChem CID	9794485
ChemSpider	7970252 checkY
UNII	JT7957Q2FB
ChEMBL	ChEMBL593430 checkY
E number	{{#property:P628}}
CompTox Dashboard (EPA)	{{#property:P3117}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C10H19NO2
Molar mass	185.267 g·mol−1
3D model (JSmol)	Interactive image
SMILES C[C@H]1CC(C[C@@H]1C)(CC(=O)O)CN
InChI InChI=1S/C10H19NO2/c1-7-3-10(6-11,4-8(7)2)5-9(12)13/h7-8H,3-6,11H2,1-2H3,(H,12,13)/t7-,8-/m0/s1 checkY Key:IUVMAUQEZFTTFB-YUMQZZPRSA-N checkY
☒NcheckY (what is this?)  (verify)

Atagabalin (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code name PD-0200390) is a drug developed by Pfizer and related to gabapentin, which similarly binds to the α₂δ calcium channels (1 and 2). It was under development as a treatment for insomnia, but was discontinued following unsatisfactory trial results. The drug reached phase 2 clinical trials for this indication prior to the discontinuation of its development.

See also

• List of investigational insomnia drugs
• 4-Methylpregabalin
• Gabapentin enacarbil
• PD-217,014
• PD-0299685